Chris Peetz
Frazier Healthcare Partners, a leading provider of growth and venture capital has announced the joining of Chris Peetz in the Life Sciences team as an Entrepreneur-in-Residence (EIR). Most recently, Mr. Peetz served as Chief Financial Officer and Head of Corporate Development at Frazier portfolio company Tobira Therapeutics, a leading developer of therapeutics to treat non-alcoholic steatohepatitis (NASH). While at Tobira, Mr. Peetz led the company’s efforts to become a public company through a reverse merger, expand its pipeline through partnerships and in-licensing, and sell the company to Allergan for total consideration of up to $1.7 billion. Prior to Tobira, Mr. Peetz held business leadership roles at Jennerex Biotherapeutics, Onyx Pharmaceuticals and Abgenix.
As an EIR with Frazier, Mr. Peetz will focus on identifying and in-licensing assets into a newly formed search company, Flashlight Therapeutics. Mr. Peetz serves as the CEO of Flashlight, which is broadly focused on oncology, liver diseases and NASH, and related areas.
“Chris played an instrumental role in the success of Tobira, and he brings unique partnering and financing insights to our team having been involved in growing companies resulting in over $15 billion in corporate transactions,” said Patrick Heron, Managing General Partner with the Frazier Life Sciences team. “He has deep experience in areas ranging from oncolytic viruses to the leading edge of NASH combination therapies, and we look forward to working with him to build a new company around in-licensed assets.”
